DDInter998 DDInter1024
Ivermectin is a semi-synthetic antiparasitic medication derived from avermectins, a class of highly-active broad-spectrum antiparasitic agents isolated from the fermentation products of _Streptomyces avermitilis_. Ivermectin itself is a mixture of two avermectins, comprising roughly 90% 5-O-demethyl-22,23-dihydroavermectin A<sub>1a</sub> (22,23-dihydroavermectin B<sub>1a</sub>) and 10% 5-O-demethyl-25-de(1-methylpropyl)-22,23-dihydro­-25-(1-methylethyl)avermectin A<sub>1a</sub> (22,23-dihydroavermectin B<sub>1b</sub>). Ivermectin is mainly used in humans in the
Lapatinib is an anti-cancer drug developed by GlaxoSmithKline (GSK) as a treatment for solid tumours such as breast and lung cancer. It was approved by the FDA on March 13, 2007, for use in patients with advanced metastatic breast cancer in conjunction with the chemotherapy drug capecitabine. Lapatinib is a human epidermal growth factor receptor type 2 (HER2/ERBB2) and epidermal growth factor receptor (HER1/EGFR/ERBB1) tyrosine kinases inhibitor. It binds to the intracellular phosphorylation domain to prevent receptor autophosphorylation upon ligand binding.
Ivermectin {u} (Compound) binds {v} (Gene) ABCB1
ABCB1 {u} (Gene) is bound by {v} (Compound) Lapatinib
Ivermectin {u} (Compound) downregulates {v} (Gene) CCNB2
CCNB2 {u} (Gene) is upregulated by {v} (Compound) Lapatinib
Ivermectin {u} (Compound) upregulates {v} (Gene) KLHDC2
KLHDC2 {u} (Gene) is upregulated by {v} (Compound) Lapatinib
Ivermectin {u} (Compound) upregulates {v} (Gene) DUSP4
DUSP4 {u} (Gene) is downregulated by {v} (Compound) Lapatinib
Ivermectin {u} (Compound) downregulates {v} (Gene) CCDC86
CCDC86 {u} (Gene) is downregulated by {v} (Compound) Lapatinib
Ivermectin {u} (Compound) causes {v} (Side Effect) Leukopenia
Leukopenia {u} (Side Effect) is caused by {v} (Compound) Lapatinib
Ivermectin {u} (Compound) binds {v} (Gene) ABCB1
ABCB1 {u} (Gene) is associated with {v} (Disease) breast cancer
breast cancer {u} (Disease) is treated by {v} (Compound) Lapatinib
Ivermectin {u} (Compound) downregulates {v} (Gene) CCNB2
CCNB2 {u} (Gene) is upregulated by {v} (Disease) breast cancer
breast cancer {u} (Disease) is treated by {v} (Compound) Lapatinib
Ivermectin {u} (Compound) downregulates {v} (Gene) POLE2
POLE2 {u} (Gene) regulates {v} (Gene) MAL
MAL {u} (Gene) is upregulated by {v} (Compound) Lapatinib
Ivermectin {u} (Compound) upregulates {v} (Gene) KLHDC2
KLHDC2 {u} (Gene) is regulated by {v} (Gene) CYP3A5
CYP3A5 {u} (Gene) is bound by {v} (Compound) Lapatinib
Ivermectin (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Lapatinib (Compound)
Ivermectin (Compound) downregulates CCNB2 (Gene) and CCNB2 (Gene) is upregulated by Lapatinib (Compound)
Ivermectin (Compound) upregulates KLHDC2 (Gene) and KLHDC2 (Gene) is upregulated by Lapatinib (Compound)
Ivermectin (Compound) upregulates DUSP4 (Gene) and DUSP4 (Gene) is downregulated by Lapatinib (Compound)
Ivermectin (Compound) downregulates CCDC86 (Gene) and CCDC86 (Gene) is downregulated by Lapatinib (Compound)
Ivermectin (Compound) causes Leukopenia (Side Effect) and Leukopenia (Side Effect) is caused by Lapatinib (Compound)
Ivermectin (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is associated with breast cancer (Disease) and breast cancer (Disease) is treated by Lapatinib (Compound)
Ivermectin (Compound) downregulates CCNB2 (Gene) and CCNB2 (Gene) is upregulated by breast cancer (Disease) and breast cancer (Disease) is treated by Lapatinib (Compound)
Ivermectin (Compound) downregulates POLE2 (Gene) and POLE2 (Gene) regulates MAL (Gene) and MAL (Gene) is upregulated by Lapatinib (Compound)
Ivermectin (Compound) upregulates KLHDC2 (Gene) and KLHDC2 (Gene) is regulated by CYP3A5 (Gene) and CYP3A5 (Gene) is bound by Lapatinib (Compound)